Osteoporosis Prevention in Early Stage Breast Cancer

早期乳腺癌的骨质疏松症预防

• 批准号: 6464250
• 负责人: DAWN HERSHMAN
• 金额: $ 13.35万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6464250
• 关键词: alendronate; bone density; breast neoplasms; chemoprevention; clinical research; drug adverse effect; drug screening /evaluation; female; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; osteoporosis; patient oriented research; women's health

DESCRIPTION (provided by applicant): In the United States, more than 2 million women are living with a history of breast cancer. Because of past advances in chemotherapy, the vast majority of women diagnosed with breast cancer will survive for many years, but they will also have increased risk for long-term complications related to estrogen deficiency, lymph node dissection, and other effects of chemotherapy on health tissue Evidence suggests that women who survive breast cancer have an increased risk for osteoporosis. This risk is highest for premenopausal women who become menopausal with chemotherapy. However, controversy exists regarding the extent of bone loss, and only a few studies have evaluated mechanisms to prevent it. A double- blind randomized control trial of weekly alendronate in premenopausal women treated with adjuvant chemotherapy for breast cancer will be performed to define and compare the changes in BMD and bone turnover that occur during and after adjuvant chemotherapy for breast cancer. We expect to characterize the natural history of bone loss during chemotherapy and define risk factors that contribute to this loss in newly diagnosed premenopausal breast cancer patients. By defining factors that predict accelerated bone loss we hope to help guide preventive therapy. With the results of this trial, cost- effectiveness of bisphosphonate treatment will be modeled. We expect that bisphosphonates will significantly reduce the rate of bone loss in this patient population and that bisphosphonate use for the prevention of osteoporosis and its related complications will be cost-effective. The training portion of this proposal includes regular mentoring with Dr. Karen Antman and Dr. Elizabeth Shane; extensive interaction with Dr. Alfred Neugut, Dr. Victor Grann, and Dr. Richard Gralla; and continued formal coursework at the Mailman School of Public Health at Columbia University. My goal as an independent investigator is to conduct clinical research that will identify approaches to cancer treatment that will minimize toxic effects, prevent long- term complications, and maximize survival, quality of life, and cost- effectiveness.

描述（由申请人提供）：在美国，超过2个 百万妇女生活在乳腺癌史上。 因为过去 化学疗法的进步，绝大多数被诊断为乳房的妇女 癌症将生存多年，但它们也将增加 与雌激素缺乏，淋巴结清扫有关的长期并发症， 化学疗法对健康组织证据的其他影响表明 在乳腺癌中生存的妇女患骨质疏松症的风险增加。 这 与绝经前妇女的风险最高 化学疗法。 但是，关于骨质流失程度存在争议 并且只有少数研究评估了预防它的机制。 双 - 绝经前妇女的每周aLendronate的盲随机对照试验 用辅助化疗治疗乳腺癌将进行 定义并比较在和 辅助化疗治疗乳腺癌。 我们希望表征 化学疗法期间骨质流失的自然病史并定义了风险因素 在新诊断的绝经前乳腺癌中导致这种损失 患者。 通过定义预测加速骨质流失的因素，我们希望 帮助指导预防疗法。 根据该试验的结果，成本 - 双膦酸盐治疗的有效性将进行建模。 我们期望这一点 双膦酸盐将显着降低这一点 患者人群和双膦酸盐用于预防 骨质疏松症及其相关并发症将具有成本效益。 这 该建议的培训部分包括与Karen博士定期指导 蚂蚁和伊丽莎白·肖恩博士；与Alfred Neugut博士的广泛互动， Victor Grann博士和Richard Gralla博士；并继续正式课程 哥伦比亚大学邮政公共卫生学院。 我作为一个目标 独立研究者将进行临床研究，以确定 癌症治疗方法可以最大程度地减少毒性作用，预防长期 术语并发症，最大化生存，生活质量和成本 - 效力。